Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q1 2025 (March 31)4holders
0new positions
0sold out
$9.66avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were Hantz Financial Services, Inc. ($1.6M), Rhumbline Advisers ($327K) and GAMMA Investing LLC ($47K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 4,857 shares bought and 4,173 shares sold, net +684 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Hantz Financial Services, Inc. | 0.03% | Add +3.1% | 161,886 | $1.6M |
| Rhumbline Advisers | 0.00% | Reduce -5.8% | 33,873 | $327K |
| GAMMA Investing LLC | 0.00% | Reduce -30.2% | 4,855 | $47K |
| PNC Financial Services Group, Inc. | 0.00% | Add +42.5% | 57 | $551 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.